Scientists that discovered a life-saving drug to treat cancer patients with a faulty gene are marking a special anniversary, and looking back at the impact their work has had around the world.

Recent FDA approvals have included Rubraca (rucaparib), which was approved in 2020 for patients with metastatic castration-resistant prostate cancer that expresses a BRCA mutation, and Lynparza ...

The addition of nivolumab to rucaparib maintenance therapy did not improve progression-free survival (PFS) in patients with ovarian cancer, outcomes of the phase 3 ATHENA-COMBO trial demonstrated. In ...

However, the approaches within these trials resemble the Olaparib trials. Rucaparib and Niraparib are being investigated in platinum sensitive ovarian cancers as a maintenance therapy (NCT01968213 ...

While immunotherapy has transformed the treatment of many cancers, it has failed to make much of an impact in advanced ovarian cancer, and AstraZeneca is hoping to change that. At ASCO, AZ ...

PARP inhibitors, which are now used as a first-line management in newly diagnosed individuals, include the FDA-approved olaparib, as well as rucaparib and niraparib. Ovarian cancer is the eighth ...

Treatment of severe infections The researchers tested the drug rucaparib and found that it can be effective in treating severe infections. The research was carried out according to the idea and under ...

Rucaparib in the TRITON3 trial showed superior progression-free survival compared to standard treatments, highlighting its efficacy in targeted patient populations. Genetic profiling is crucial for ...

RAEs could occur as soon as the first dose after Olaparib, Niraparib, Rucaparib, and Talazoparib, indicated by the identical dates of drug administration and RAE onset in the database. We identified a ...